Using an antibody that detects H‐2Kb bound to SIINFEKL (OVA257‐264) peptide, we found that knockdown (Figure5A) or pharmacological inhibition (Figure 5B) of GLS in tumor cells enhanced MHC‐I‐mediated OVA antigen presentation and this increased presentation was not due to the alteration of intracellular OVA expression levels (Figure 5C). The gene discussed is GLS; the disease is neoplasm.